Cubist Systematic Strategies LLC Has $197,000 Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Cubist Systematic Strategies LLC boosted its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 64.1% in the fourth quarter, HoldingsChannel reports. The firm owned 11,990 shares of the biotechnology company’s stock after buying an additional 4,682 shares during the period. Cubist Systematic Strategies LLC’s holdings in Anika Therapeutics were worth $197,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ANIK. Alta Fundamental Advisers LLC lifted its stake in shares of Anika Therapeutics by 136.6% in the fourth quarter. Alta Fundamental Advisers LLC now owns 700,432 shares of the biotechnology company’s stock valued at $11,529,000 after buying an additional 404,350 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Anika Therapeutics by 431.9% in the fourth quarter. JPMorgan Chase & Co. now owns 82,491 shares of the biotechnology company’s stock valued at $1,358,000 after buying an additional 66,982 shares in the last quarter. Capital Management Corp VA lifted its position in shares of Anika Therapeutics by 12.1% during the fourth quarter. Capital Management Corp VA now owns 325,545 shares of the biotechnology company’s stock valued at $5,358,000 after purchasing an additional 35,195 shares in the last quarter. Boothbay Fund Management LLC lifted its position in shares of Anika Therapeutics by 5.1% during the fourth quarter. Boothbay Fund Management LLC now owns 529,503 shares of the biotechnology company’s stock valued at $8,716,000 after purchasing an additional 25,665 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Anika Therapeutics during the fourth quarter valued at about $352,000. 91.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ANIK has been the topic of a number of recent analyst reports. Barrington Research dropped their price target on shares of Anika Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Monday, May 12th. StockNews.com lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 12th. Finally, B. Riley initiated coverage on shares of Anika Therapeutics in a research report on Thursday, April 17th. They set a “buy” rating and a $21.00 price target on the stock.

Anika Therapeutics Stock Performance

Shares of ANIK stock opened at $12.19 on Monday. The firm has a market cap of $174.82 million, a price-to-earnings ratio of -1.83 and a beta of 0.76. Anika Therapeutics, Inc. has a 52 week low of $11.11 and a 52 week high of $29.12. The firm’s 50-day simple moving average is $14.32 and its two-hundred day simple moving average is $16.04.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings data on Wednesday, March 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.13). The company had revenue of $30.60 million during the quarter, compared to the consensus estimate of $29.00 million. Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. Analysts forecast that Anika Therapeutics, Inc. will post -0.84 earnings per share for the current year.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.